PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

Why It Matters

The results signal accelerating adoption of robotic BPH therapy and validate PROCEPT’s AI‑driven platform, yet the continued loss underscores the need for sustained cash to fund expansion and clinical trials.

Key Takeaways

• Q1 revenue $83.1M, up 20% YoY.
• U.S. procedures rose 30% to ~12,200.
• Hydros install base 765 systems, 40% YoY growth.
• Gross margin improved to 65%, up 1 point.
• Cash $249M fuels R&D and AI software rollout.

Pulse Analysis

PROCEPT BioRobotics’ first‑quarter performance highlights a pivotal moment for the urology robotics market. Revenue growth outpaced the broader medical device sector, reflecting heightened physician confidence in Aquablation therapy and the company’s strategic focus on operational discipline. The 30% jump in U.S. procedures and a 40% expansion of the Hydros install base illustrate deepening market penetration, driven by the technology’s ability to treat benign prostatic hyperplasia (BPH) across a wide range of prostate sizes without the steep learning curve associated with traditional surgery.

The financial picture, however, remains mixed. While gross margin improved to 65%—a modest gain from the prior year—operating expenses rose sharply as PROCEPT invests in commercial rollout, AI software development, and the WATER IV prostate cancer trial. The resulting net loss of $31.6 million underscores the capital‑intensive nature of scaling a niche surgical platform. Nonetheless, a robust cash reserve of $249 million provides a runway to sustain R&D, support the newly cleared FirstAssist AI suite, and navigate the short‑term disruption from recent commercial realignment.

Looking ahead, the company’s guidance of $390‑$410 million in full‑year revenue suggests a 27%‑33% growth trajectory, positioning PROCEPT as a key player in the emerging AI‑enabled surgical robotics space. If the AI enhancements translate into higher procedure volumes and pricing power, the firm could narrow its loss margin and move toward profitability. Investors will watch adoption rates, reimbursement trends, and the outcomes of ongoing clinical trials as critical levers influencing long‑term valuation.